Roche’s Alecensa approved in Europe, with head-to-head data coming
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
Approval by May could put Keytruda in pole position
A decisive moment in lung cancer treatment is nearing
BMS and Nektar’s combination latest in frenzied immunotherapy field
Merck steals a march on rival BMS.
Analysts expect Opdivo to recover via combination trials
Tagrisso could help revive sales after patent losses.
Patients in Scotland will receive lung cancer drug, those in England will not.